Summary: A new study reveals that psilocybin, the active ingredient in “magic mushrooms,” is as effective as a standard SSRI in treating depression over a 6-month period, while potentially offering extra advantages in well-being and psychosocial functioning.
Estimated reading time: 5 minutes
A groundbreaking study has found that psilocybin, the psychedelic compound found in certain mushrooms, may offer comparable long-term antidepressant effects to standard SSRI medications. The research, presented at the European College of Neuropsychopharmacology (ECNP) Congress in Milan, suggests that psilocybin could provide additional benefits in terms of overall well-being and psychosocial functioning.
Psilocybin vs. Escitalopram: A Head-to-Head Comparison
The study, conducted by researchers at Imperial College London, directly compared psilocybin to escitalopram, a commonly prescribed SSRI antidepressant. Both treatments showed similar improvements in depressive symptoms over a 6-month period. However, psilocybin appeared to outperform escitalopram in several key areas.
Mr. Tommaso Barba, a PhD candidate from Imperial College London and lead researcher on the study, explained: “This is the first work to compare the long-term effects of these two drugs in the context of overall well-being, not just freedom from depression. In previous work we had found that both treatments led to comparable improvements in alleviating symptoms of depression at the 6-week mark, such as sadness and negative emotions. However, this work shows that psilocybin outperformed escitalopram in several measures of well-being, meaning in life, work and social functioning.”
The study involved 59 patients with moderate to severe depression. Thirty participants received a single dose of psilocybin, while 29 were given a six-week course of escitalopram. Both groups received similar psychological support totaling around 20 hours.
Beyond Symptom Relief: Additional Benefits of Psilocybin
One of the most intriguing findings of the study was that psilocybin appeared to offer benefits beyond mere symptom relief. Patients treated with psilocybin reported greater improvements in social functioning and psychological connectedness compared to those taking escitalopram.
Dr. David Erritzoe, Clinical Director and Deputy Head of the Centre for Psychedelic Research at Imperial College London, highlighted the significance of these findings: “This is important because improving connectedness and having greater meaning in life can significantly enhance a person’s quality of life and long-term mental health. The study suggests that psilocybin therapy might be a more holistic treatment option for depression, addressing both the symptoms of depression and overall well-being.”
Another potential advantage of psilocybin over SSRIs is its effect on sexual function. Previous research has shown that psilocybin may improve sexual drive, in contrast to SSRIs, which often lower libido in many patients.
Cautions and Considerations
While the results are promising, the researchers emphasize that psilocybin remains an experimental drug and has not been approved for general use. Dr. Erritzoe cautioned: “Psilocybin is still an experimental drug; it has not yet been approved for general use. It is administered in highly controlled and protected environments: these precautions are not found in recreational psychedelic use, which is known for having unpredictable and potentially harmful effects, especially for vulnerable people struggling with mental health issues.”
It’s also important to note that the study only treated patients for 6 weeks, and many participants received additional treatments during the 6-month follow-up period. Further research is needed to fully understand the long-term effects and potential risks of psilocybin-assisted therapy.
The Future of Depression Treatment
As the field of psychedelic medicine continues to evolve, studies like this one provide valuable insights into potential new treatment options for depression. While SSRIs remain an effective treatment for many patients, psilocybin may offer an alternative for those who don’t respond well to conventional antidepressants or who are seeking a more holistic approach to mental health.
Mr. Barba concluded: “SSRIs work well, but not for everyone. They are also associated with some side effects. However this work implies that psilocybin generally seems to offer a real alternative, and perhaps additional benefits, to people who are worried about taking conventional antidepressants.”
As research progresses, it’s likely that we’ll see a more nuanced and personalized approach to depression treatment, potentially incorporating both traditional pharmaceuticals and psychedelic-assisted therapies.
Quiz
- What was the main finding of the study comparing psilocybin to escitalopram?
- In addition to improving depressive symptoms, what other benefits did psilocybin offer compared to escitalopram?
- What caution did Dr. Erritzoe emphasize regarding psilocybin use?
Answer Key:
- Psilocybin showed comparable long-term antidepressant effects to escitalopram over a 6-month period.
- Psilocybin led to greater improvements in social functioning, psychological connectedness, and potentially sexual drive.
- Psilocybin is still an experimental drug and should only be administered in controlled, protected environments.
Further Reading
- Imperial College London: Psychedelic Research Centre
- National Institute of Mental Health: Depression
- FDA: Breakthrough Therapy Designation for Psilocybin
Glossary of Terms
- Psilocybin: The active psychedelic compound found in certain species of mushrooms.
- SSRI: Selective Serotonin Reuptake Inhibitor, a class of antidepressant medications.
- Escitalopram: A specific SSRI medication used to treat depression and anxiety disorders.
- Psychedelic: A class of hallucinogenic substances that alter perception, mood, and cognitive processes.
- Psychosocial functioning: An individual’s ability to perform daily activities and interact effectively with their environment and other people.
- Double-blind randomized controlled trial: A study design where neither participants nor researchers know who is receiving which treatment, used to minimize bias.
Enjoy this story? Get our newsletter! https://scienceblog.substack.com
